37 research outputs found
Analyzing GPCR-Ligand Interactions with the Fragment Molecular Orbital (FMO) Method
G-protein-coupled receptors (GPCRs) have enormous physiological and biomedical importance, and therefore it is not surprising that they are the targets of many prescribed drugs. Further progress in GPCR drug discovery is highly dependent on the availability of protein structural information. However, the ability of X-ray crystallography to guide the drug discovery process for GPCR targets is limited by the availability of accurate tools to explore receptor-ligand interactions. Visual inspection and molecular mechanics approaches cannot explain the full complexity of molecular interactions. Quantum mechanics (QM) approaches are often too computationally expensive to be of practical use in time-sensitive situations, but the fragment molecular orbital (FMO) method offers an excellent solution that combines accuracy, speed, and the ability to reveal key interactions that would otherwise be hard to detect. Integration of GPCR crystallography or homology modelling with FMO reveals atomistic details of the individual contributions of each residue and water molecule toward ligand binding, including an analysis of their chemical nature. Such information is essential for an efficient structure-based drug design (SBDD) process. In this chapter, we describe how to use FMO in the characterization of GPCR-ligand interactions
Remifentanil for labour analgesia: a double‐blinded, randomised controlled trial of maternal and neonatal effects of patient‐controlled analgesia versus continuous infusion
Thienobenzothiopyranones III new 4H-thieno[2,3-b][1]benzothiopyran-4-ones carrying different heterocyclic moieties of expected pharmacological interest
Synthesis of 2-substituted 4H-thieno[2,3-b][1]benzothiopyran-4-ones as potential chemotherapeutic agents
Additional file 1 of Discovery of a new potent oxindole multi-kinase inhibitor among a series of designed 3-alkenyl-oxindoles with ancillary carbonic anhydrase inhibitory activity as antiproliferative agents
Additional file 1. S1. Spectral data. S2. Molecular docking study. S3. In Vitro biological activity